Prelude Therapeutics Inc (PRLD): Cash & Equivalents
$35.26M
As of 2025-12-31
$26.33M
As of 2026-06-30
+4.8%
3-year compound annual growth
-30.6%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $35.26M | +182.6% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $12.47M | -50.7% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $25.29M | -17.4% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $30.61M | -3.8% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $31.83M | -85.4% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $218.31M | n/m | 2022-03-17, Balance as of period end |
| 2019-12-31 | $18.88M | n/a | 2021-03-16, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $35.26M | +182.6% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $2.13M | +53.1% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $968.0K | -87.9% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $44.06M | +171.1% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $207.64M | +110.2% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $7.49M | +192.2% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $213.19M | +513.2% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $15.42M | -20.8% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.01M | -50.4% |
Compare PRLD, EMMA, JAGX, EVMN side by side · Screen every company in Pharmaceutical Preparations ↗